linjc16/ctgov huggingface dataset:
A Modeling of Changes in Tidal Volume With Concentration of Inhalational Anesthetics

Study Overview
=================
Brief Summary
-----------------
modelling of tidal volume with inhalational anesthetic concentration

Detailed Description
-----------------
The investigators would like to develop the modelling of tidal volume with inhalational anesthetic concentration during spontaneous breathing during general anesthesia in children

Official Title
-----------------
A Modeling of Changes in Tidal Volume With Concentration of Inhalational Anesthetics Under General Anesthesia Using Laryngeal Mask Airway

Conditions
-----------------
Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - general anesthesia Exclusion Criteria: -

Ages Eligible for Study
-----------------
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concentration | inhalational anesthetic concentration | 20 minutes |
Contamination of Hospital Scrubs

Study Overview
=================
Brief Summary
-----------------
This study will test if nurses wearing scrubs treated with an antimicrobial agent while performing patient care will: - Decrease the amount of bacterial contamination on scrubs at the end of a typical hospital shift during routine use after home laundering This study will gather information by obtaining swabs from scrubs treated with an antimicrobial and from non-treated scrubs.

Detailed Description
-----------------
The outcome of interest is the contamination of scrubs with Staphylococcus aureus, Enterococcus species or Gram-negative bacteria as determined by surface swabs of healthcare worker scrubs after a full 8-hour shift. The outcomes will be analyzed both individually and collectively. Contamination will be defined as: - A swab that is determined to be positive for any Staphylococcus aureus, Enterococcus species, or Gram-negative bacteria after a hospital shift.

Official Title
-----------------
A Novel Agent to Decrease Contamination of Hospital Scrubs

Conditions
-----------------
Bacterial Contamination

Intervention / Treatment
-----------------
* Other: Antimicrobial impregnated scrubs
* Other: Non-impregnated scrubs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nursing staff engaging in direct patient care Working in select/participating intensive care and intermediate care units Working at least 8 day shifts in one month (study period) Exclusion Criteria: Pregnant Unable to provide consent Unable to follow study schedule

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Antimicrobial impregnated scrubs<br>Those randomized to this arm of the study will wear scrubs impregnated with an antimicrobial. | Other: Antimicrobial impregnated scrubs<br>* Scrubs are impregnated with an antimicrobial product<br>|
| Placebo Comparator: Non-impregnated scrubs<br>Those randomized to this arm of the study will wear scrubs not impregnated with an antimicrobial. | Other: Non-impregnated scrubs<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bacterial contamination of scrubs | Contamination will be defined as: A swab that is determined to be positive for any of Staphylococcus aureus, Enterococcus species, or Gram-negative bacteria after a hospital shift. | Outcome will be assessed at the end of the hospital shift ( approx 8 hours) |
Predicting Lung Injury From Transfusion in Patients With Liver Disease

Study Overview
=================
Brief Summary
-----------------
A certain molecule floating in the blood may represent a risk of lung injury after a transfusion. We are determining whether detection of this molecule on a simple blood clotting test will predict the development of lung injury due to transfusion in bleeding patients with chronic liver disease.

Official Title
-----------------
Endogenous Heparinoid Interference With Coagulation on Thromboelastogram as a Predictive Biomarker for Transfusion Related Acute Lung Injury (TRALI)

Conditions
-----------------
Transfusion-related Acute Lung Injury, Chronic Liver Disease, Gastrointestinal Bleeding

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Subjects will be eligible to participate in the study if they meet all of the following criteria: Admit to an ICU due to gastrointestinal bleeding AND an INR > 1.5 Patient has chronic liver disease defined as 1 or more of the three following diagnostic criteria: Previous diagnosis of chronic liver disease OR Imaging or biopsy diagnosis of cirrhosis Signs of portal hypertension (ascites, varices, hypersplenism) Laboratory evidence of synthetic dysfunction (INR>1.5, Bilirubin> 2.0, Albumin< 2.5) AND ≥2 physical exam findings on admission associated with chronic liver disease (palmar erythema, spider angiomata, asterixis, caput medusa, gynecomastia) Exclusion criteria: Subjects will be ineligible to participate in the study if they meet any of the following criteria Patient under age 18 OR pregnant OR incarcerated Patient meets criteria for acute respiratory distress syndrome (ARDS) (PaO2/FiO2<165) Patient admitted to ICU for re-bleed on same hospital admission OR has already received >4 units of plasma. History of inheritable or acquired clotting or bleeding disorder Patient actively anticoagulated or has recently received (within 72h) vitamin K antagonists, direct thrombin inhibitors, heparins or Xa antagonists

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TRALI (consensus definition- with exception of absence of other acute lung injury risk factors) |  | 0-54 hours post enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in ratio of partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) |  | 0-54 hours post enrollment | 
| Bleeding complications | Baveno V criteria | 0-5 days post-enrollmnet | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastrointestinal hemorrhage, respiratory distress syndrome, adult, blood component transfusion, blood coagulation
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and proton pump inhibitors (PPIs) in patients with serious coronary heart disease using two UK primary care databases.

Detailed Description
-----------------
Number of Anticipated Subjects: In case-control analysis: 10.000-15.000 participants

Official Title
-----------------
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death - Nested Case Control Analyses in a Cohort of Patients With Acute Serious Coronary Heart Disease

Conditions
-----------------
Nonfatal Myocardial Infarction, Coronary Death

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: As above ( study population description). All individuals aged 50-84 years with at least one year of enrolment with the primary care physician (PCP) and a computerized prescription history of at least one year before the start of the study. Exclusion Criteria: Recorded diagnosis of cancer prior to study start. Patients aged ≥ 70 years with a follow-up longer than one year if having fewer than two recorded consultations with a primary care physician (PCP) during their entire follow-up (proxy for incomplete and invalid data recording

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 84 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases<br>Cases with nonfatal MI or coronary death | |
| Controls<br>Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nonfatal MI or coronary death |  | Up to eight years from entry into study cohort | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MI, low dose aspirin, PPI, epidemiology, Nonfatal MI and coronary death
The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study

Study Overview
=================
Brief Summary
-----------------
The current study is an open, non-randomized, monocentric, and interventional study. CoViD-19 patients will be recruited at UZ Brussel after informed consent is obtained. Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection. Sample storage and subsequent use in fundamental research will be performed at VUB Neuro-Aging and Viro-Immunotherapy. Additionally, medical records of UZ Brussel will be searched and epidemiological, clinical, radiological, and biological data of the selected patients will be obtained at the diagnosis time point and during follow-up. Healthy volunteers will be recruited as well in the current study, as a comparison arm, after informed consent is obtained.

Official Title
-----------------
The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study

Conditions
-----------------
Complement Abnormality, Peripheral Blood Mononuclear Cells, Covid19

Intervention / Treatment
-----------------
* Other: Blood analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Covid-19 patients Inclusion Criteria: Positive nasopharyngeal reverse transcriptase-polymerase chain reaction for SARS-Coronavirus-02 Signed inform consent Healthy Volunteers Inclusion Criteria: Signed inform consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Covid-19 patients<br>Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection | Other: Blood analysis<br>* Venipuncture and collection of serum and whole blood<br>|
| Other: Controle<br>Whole blood and serum samples will be collected during the same period | Other: Blood analysis<br>* Venipuncture and collection of serum and whole blood<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in complements or peripheral blood mononuclear cells between CoViD-19 patients and controls |  | up to 1 year |
Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease

Study Overview
=================
Brief Summary
-----------------
The goal of the study is to investigate the impact of a 4 week treatment with pioglitazone (in comparison to placebo) on biomarkers for atherosclerosis and cardiovascular risk, as well as the degree of activation of the immune system, when given on top of an anti-diabetic treatment (metformin and/or sulfonylurea drugs) that has already resulted in good glycemic control.

Detailed Description
-----------------
PPARgamma activation by pioglitazone has shown to be associated with an improvement of cardiovascular risk when measured with clinical (assessement of intima-media-thickness) or biochemical (hsCRP, MMP-9 etc.) markers. Well controlled patients (HbA1c < 8.0 %) will receive either pioglitazone or placebo (randomised, double-blind) for 4 weeks. Blood will be drawn to investigate the change in cardiovascular or metabolic markers and mRNA will be isolated from circulating mononuclear cells to investiagte the degree of activation of the immune system, which is another measure for the risk of atherosclerosis development.

Official Title
-----------------
Effects of Pioglitazone in Patients With Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Vascular Complications : A Placebo-Controlled Study

Conditions
-----------------
Type 2 Diabetes Mellitus, Cardiovascular Disease

Intervention / Treatment
-----------------
* Drug: pioglitazone
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: type 2 diabetes mellitus stable oral treatment with metfromin and/or sulfonylurea age 20 - 80 years angiographically confirmed atherosclerosis or hsCRP > 1 mg/l Exclusion Criteria: type 1 diabetes HbA1c > 8.5 % severe disease acute coronary syndrome contraindications to pioglitazone (heart failure etc.)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pioglitazone<br> | Drug: pioglitazone<br> <br> |
| Active Comparator: placebo<br> | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short-term effect of Pioglitazone on Markers of vascular risk (MMP-9, hsCRP, monocyte activation) |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety |  | 4 weeks | 
| Metabolic control (HbA1c, Glucose) |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes mellitus, monocyte activation, cardiovascular risk
The Five-repetition Sit-to-stand Test for Lower Back Pain or Radiculopathy

Study Overview
=================
Brief Summary
-----------------
The five-repetition sit-to-stand test (5R-STS) has been used in many medical disciplines, but has never been correlated with or validated in regard to degenerative spinal diseases. The investigators aim to assess the possibility of using the standardized 5R-STS as an objective measure of functional impairment and pain severity in patients with degenerative lumbar spinal diseases.

Official Title
-----------------
The Five-repetition Sit-to-stand Test as an Objective Measure of Functional Impairment in Patients With Lower Back Pain or Radiculopathy

Conditions
-----------------
Degenerative Disc Disease, Degenerative Spondylolisthesis, Herniated Disc, Stenosis, Spinal, Nerve Root Compress;Lumbosac

Participation Criteria
=================
Eligibility Criteria
-----------------
This study will include 100 Patients: Inclusion Criteria: Degenerative diseases of the lumbar spine (Herniated disc, lumbar stenosis, spondylolisthesis, degenerative disc disease) Symptoms of lower back pain, neurogenic claudication, or radiculopathy Exclusion Criteria: Hip or Knee prosthetics Walking aides This study will also include 25 healthy volunteers: Inclusion Criteria: - No degenerative spinal or lower extremity complaints Exclusion Criteria: Back pain, leg pain, other lower extremity-related complaints Knee or hip prosthetics Walking aides
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 5R-STS | The result of the standardized 5R-STS in seconds. If the patient is unable to complete the test, the results is noted as not possible. | 0 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS back pain | Validated questionnaire (VAS BP) will be used to correlate the 5R-STS results with validated measures of functional impairment and pain severity. | 0 weeks | 
| VAS leg pain | Validated questionnaire (VAS LP) will be used to correlate the 5R-STS results with validated measures of functional impairment and pain severity. | 0 weeks | 
| EQ-5D-3L | Validated questionnaire (EQ-5D-3L) will be used to correlate the 5R-STS results with validated measures of functional impairment and pain severity. | 0 weeks | 
| Oswestry Disability Index | Validated questionnaire (ODI) will be used to correlate the 5R-STS results with validated measures of functional impairment and pain severity. | 0 weeks | 
| Roland-Morris-Disability Questionnaire | Validated questionnaire (RMDBQ) will be used to correlate the 5R-STS results with validated measures of functional impairment and pain severity. | 0 weeks |
Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis

Study Overview
=================
Brief Summary
-----------------
This study was designed to test the hypothesis that, irrespective of the degree of interstiaI lung disease and/or pulmonary arterial hypertension, the combined measurement of lung diffusing capacity for nitric oxide and carbon monoxide, might be useful to provide a mechanistic interpretation of changes of diffusion subcomponents in systemic sclerosis (SSc).

Detailed Description
-----------------
In systemic sclerosis (SSc) the impairment of lung function is generally inferred from measurements of forced vital capacity (FVC) and standard lung diffusing capacity for carbon monoxide (DLCO). However, FVC measurement does not provide an accurate estimate of lung restriction and DLCO does not allow separate the alveolar membrane (DMCO) from erythrocyte (DeCO) diffusive conductance for CO. Previous studies have shown that DMCO and DeCO may change irrespective of overt intersitial lung disease (ILD) and/or pulmonary arterial hypertension (PAH). These changes may be consistent with a limitation of alveolar-capillary erythrocyte recruitment which impairs DM.This study was designed to test the hypothesis that, irrespective of the degree of ILD and/or PAH, combined DLNO-DLCO measurement might be useful to provide a mechanistic interpretation of DM and De changes in SSc.

Official Title
-----------------
Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis

Conditions
-----------------
Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients fulfilling the 2013 American College of Rheumatology/European League Against Rheumatism criteria for a definite diagnosis of SSc with a total score ≥9 Exclusion Criteria: unstable subjects and/or who have suffered from respiratory exacerbations in the previous 4-wk
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung diffusing capacity for nitric oxide | Alveolar-capillary gas exchange | 2 hours |
Age-related Changes of Crystalline Lens Tilt and Decentration: A Swept-source Optical Coherence Tomography Study

Study Overview
=================
Brief Summary
-----------------
230 participants at Eye Hospital of Wenzhou Medical University during June, 2019 and August, 2019 were enrolled in this study. 230 right eyes and 88 left eyes were included for the measurement. All the measurements were performed under non-mydriatic conditions in a dim examination room using the CASIA2 swept-source AS-OCT system.

Official Title
-----------------
Age-related Changes of Crystalline Lens Tilt and Decentration: A Swept-source Optical Coherence Tomography Study

Conditions
-----------------
Crystalline Cataract, Lens; Anomaly

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria： healthy volunteers and patients with age-related cataract Exclusion Criteria: aphakia or pseudophakia any other ocular diseases with the exception of senile cataract any history of ocular surgery fixation difficulties caused by any reasons
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| under 18 years old<br> | |
| 18-40 years old<br> | |
| 41-60 years old<br> | |
| over 60 years old<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| crystalline lens tilt | magnitude and direction of crystalline lens lilt | 2020.4.30 | 
| crystalline lens decentration | magnitude and direction of crystalline lens decentration | 2020.4.30 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
crystalline lens tilt, crystalline lens decentration, swept-source optical coherence tomography